Rank #1133DVAX

Dynavax Technologies Corporatio

$15.50

0.00% (Daily)

Market Cap

$1.82B

Revenue

$330.51M

Rank by MCap

#1133

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Ryan Spencer

Headquarters

EmeryVille, CA

Employees

405

About Dynavax Technologies Corporatio

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vac...